Plain English Summary
Background and study aims
This study aims to evaluate the effectiveness and cost-effectiveness of collaborative care in treating the symptoms of depression in patients who have coronary heart disease (CHD) and/or diabetes. Collaborative care is a method of care management in which the patient, medical doctors and other specialists collaborate to design and deliver a structured care programme for the patient. In the USA there is a lot of evidence suggesting that collaborative care may be beneficial to patients with depression as well as CHD and/or diabetes.
Who can participate?
The study is open to patients aged 18 and over in the North West of the UK who have a diagnosis of CHD and/or diabetes as well as depressive symptoms.
What does the study involve?
General practice surgeries that enter the study are randomly allocated to provide either collaborative care or usual care for patients who are participating in the study.
What are the possible benefits and risks of participating?
Participants will have the chance to receive collaborative care, which has been shown to reduce symptoms of depression for CHD and/or diabetes patients in the USA. We do not anticipate any side effects, risks or disadvantages for people who participate in this study.
Where is the study run from?
COllaborative INterventions for CIrculation and DEpression (COINCIDE): Care for depression in people with diabetes and/or coronary heart disease
Depression is a prevalent issue for patients suffering from long term conditions (LTC) such as diabetes or coronary heart disease. Patients who experience depression alongside a LTC may find it more difficult to manage their illness properly and experience a poorer standard of health. Effective treatments for depression are available but are under-prescribed for patients with LTCs as depression is frequently undetected and may be viewed by both patients and health professionals as a normal consequence of ill health.
The COINCIDE trial will test the effectiveness of collaborative care in the UK for patients with depression and a long-term condition.